Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance.

Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI.

Arthritis Res Ther. 2012 Jun 12;14(3):R141. doi: 10.1186/ar3874.

2.

Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.

Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, Viana VS, Bonfá E, Siqueira JT.

J Clin Rheumatol. 2012 Jun;18(4):180-4. doi: 10.1097/RHU.0b013e31825828be.

PMID:
22647860
3.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

Arthritis Rheum. 2007 May;56(5):1417-23.

4.

Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.

Van Doornum S, McColl G, Wicks IP.

Rheumatology (Oxford). 2005 Nov;44(11):1428-32. Epub 2005 Aug 2.

5.

Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.

Hayashi M, Kojima T, Funahashi K, Kato D, Matsubara H, Shioura T, Kanayama Y, Hirano Y, Ishiguro N.

Mod Rheumatol. 2012 Jun;22(3):363-9. doi: 10.1007/s10165-011-0527-3. Epub 2011 Oct 7.

PMID:
21979824
6.
7.

Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.

Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P.

Joint Bone Spine. 2012 Dec;79(6):591-6. doi: 10.1016/j.jbspin.2012.02.003. Epub 2012 Apr 4.

PMID:
22480748
8.

Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.

Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J.

Clin Exp Rheumatol. 2006 Jan-Feb;24(1):83-6.

PMID:
16539824
9.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

10.

Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis.

Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nightingale P, Koutedakis Y, Kitas GD.

Arthritis Res Ther. 2012 Jul 5;14(4):R160. doi: 10.1186/ar3900.

12.

Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?

Cuchacovich R, Espinoza LR.

Clin Rheumatol. 2009 Oct;28(10):1217-20. doi: 10.1007/s10067-009-1208-x. Epub 2009 Jun 11.

PMID:
19517156
13.

Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.

J Rheumatol. 2011 Nov;38(11):2346-54. doi: 10.3899/jrheum.101295. Epub 2011 Oct 1.

PMID:
21965648
14.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
15.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
16.

Systemic blockade of TNF-α does not improve insulin resistance in humans.

Ferraz-Amaro I, Arce-Franco M, Muñiz J, López-Fernández J, Hernández-Hernández V, Franco A, Quevedo J, Martínez-Martín J, Díaz-González F.

Horm Metab Res. 2011 Oct;43(11):801-8. doi: 10.1055/s-0031-1287783. Epub 2011 Oct 18.

PMID:
22009376
17.

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

Finckh A, Simard JF, Gabay C, Guerne PA; SCQM physicians.

Ann Rheum Dis. 2006 Jun;65(6):746-52. Epub 2005 Dec 8.

18.

Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy.

McGeough CM, Berrar D, Wright G, Mathews C, Gilmore P, Cunningham RT, Bjourson AJ.

Rheumatol Int. 2012 Jun;32(6):1647-53. doi: 10.1007/s00296-011-1838-6. Epub 2011 Mar 4.

19.

Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.

Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.

J Rheumatol. 2007 Dec;34(12):2334-42. Epub 2007 Nov 1.

PMID:
17985409
20.

Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.

Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G; Gruppo Italiano di Studio sulle Early Arthritides (GISEA).

J Rheumatol. 2012 Jun;39(6):1179-84. doi: 10.3899/jrheum.111125. Epub 2012 Apr 1.

PMID:
22467933
Items per page

Supplemental Content

Write to the Help Desk